Lakhmir Chawla - La Jolla Chief Medical Officer

LJPCDelisted Stock  USD 6.22  0.00  0.00%   

Executive

Dr. Lakhmir S. Chawla is the Chief Medical Officer of the Company. He has more than 20 years of medical experience with particular expertise in critical care and nephrology. Dr. Chawla was an active investigator in the field of critical care nephrology since 2002. Previously, Dr. Chawla was an Associate Professor of Medicine at the George Washington University from 2008 to 2015, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla was also the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center from 2014 to 2015. During his tenure at George Washington, Dr. Chawla was the designer and lead investigator of a pilot study called the ATHOS trial, which served as the basis for the Companys ongoing ATHOS 3 clinical study. Dr. Chawla received an M.D. from the New Jersey Medical School. since 2015.
Age 46
Tenure 9 years
Phone617 715-3600
Webwww.ljpc.com

La Jolla Management Efficiency

The company has return on total asset (ROA) of 1.64 % which means that it generated a profit of $1.64 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0544 %, meaning that it created $0.0544 on every $100 dollars invested by stockholders. La Jolla's management efficiency ratios could be used to measure how well La Jolla manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 124.8 M in liabilities with Debt to Equity (D/E) ratio of 7.16, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. La Jolla Pharmaceutical has a current ratio of 3.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist La Jolla until it has trouble settling it off, either with new capital or with free cash flow. So, La Jolla's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like La Jolla Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for LJPC to invest in growth at high rates of return. When we think about La Jolla's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Pat WadorsServiceNow
52
Patricia WadorsServiceNow
54
Matt WaldieEastern Co
N/A
Sandra FrithiofCalliditas Therapeutics
49
Andrew GreenebaumSkechers USA
N/A
Pete CalichmanSkechers USA
N/A
Andrew BettsEastern Co
N/A
Richard AndersonEastern Co
N/A
Rachelle LedgerEastern Co
N/A
MBA CPFABausch Lomb Corp
64
Louise BolgerEastern Co
N/A
T CrawfordBausch Lomb Corp
N/A
Chirantan DesaiServiceNow
53
Asli GevgililiBausch Lomb Corp
N/A
Jonathon KellermanBausch Lomb Corp
N/A
Yehia MDBausch Lomb Corp
57
A BaileyBausch Lomb Corp
61
Theresa DewsEastern Co
N/A
Ernie HawkinsEastern Co
N/A
Teona JohnsonCalliditas Therapeutics
N/A
David FerraroCalliditas Therapeutics
N/A
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. La Jolla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 61 people. La Jolla Pharmaceutical (LJPC) is traded on NASDAQ Exchange in USA and employs 61 people.

Management Performance

La Jolla Pharmaceutical Leadership Team

Elected by the shareholders, the La Jolla's board of directors comprises two types of representatives: La Jolla inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LJPC. The board's role is to monitor La Jolla's management team and ensure that shareholders' interests are well served. La Jolla's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, La Jolla's outside directors are responsible for providing unbiased perspectives on the board's policies.
George Tidmarsh, President CEO, Secretary, Director
Saiid Zarrabian, Independent Chairman of the Board
James Rolke, VP of RandD
Chester Zygmont, Director of Finance
Craig Johnson, Independent Director
Jennifer Carver, Senior Vice President Operations
Robert Rosen, Director
Lakhmir Chawla, Chief Medical Officer
Laura Douglass, Independent Director
Dennis Mulroy, CFO
Darryl Wellinghoff, Chief Commercial Officer

LJPC Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is La Jolla a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards La Jolla in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, La Jolla's short interest history, or implied volatility extrapolated from La Jolla options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in LJPC Stock

If you are still planning to invest in La Jolla Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the La Jolla's history and understand the potential risks before investing.
Stocks Directory
Find actively traded stocks across global markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Transaction History
View history of all your transactions and understand their impact on performance
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format